在澳大利亚炎症性关节炎队列中,自我报告的抗风湿药物和制药索赔之间的协议
Tom Lynch1, Claire Barrett2, Rachel Black3
1Sydney Musculoskeletal Health, Kolling Institute, Faculty of Medicine and Health, The University of Sydney and the Northern Sydney Local Health District and Florance and Cope Professorial Department of Rheumatology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
ACR open rheumatology
|October 17, 2025
概括
炎症性关节炎患者的药物自我报告与处方数据有中等到高的一致性. 诸如整体健康状况较差和残疾等因素可能会影响这些药物的自我报告准确性.
科学领域:
- 类风湿病学 类风湿病学
- 药学流行病学 药学流行病学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 准确的药物数据对于了解炎症性关节炎的治疗模式和结果至关重要.
- 自我报告的药物使用在研究中很常见,但其与客观数据的一致性,如处方要求,需要评估.
研究的目的:
- 在炎症性关节炎队列中,评估自我报告的药物使用和处方要求数据之间的一致性.
- 为了确定自我报告和分发的药物数据之间的差异的预测因素.
主要方法:
- 对疾病修饰性抗风湿药物 (DMARD),葡萄糖皮质类药物和止痛药的纵向问卷数据 (2012-2023) 与制药福利计划发行数据进行了比较.
- 在各种回顾窗口 (1-12个月) 中,使用科恩的kappa,灵敏度,正预测值 (PPV) 和负预测值 (NPV) 来衡量协议.
- 多变量后勤回归被用来探索不一致的自我报告的预测因素.
主要成果:
- 对于DMARDs (κ 0.67-0.95) 和处方非阿片类止痛药/口服类固醇 (κ 0.66-0.80) 观察到实质性至高的协议.
- 对于处方阿片类止痛药 (κ 0.48-0.7) 发现了中等至实质性的协议.
- 3个月的回顾窗口通常优化了协议,较长的窗口改善了特定药物的一致性. 较大的自我评估残疾和较差的健康状况与不和有关.
结论:
- 在炎症性关节炎患者中,自我报告的药物使用表明与处方声明数据的中度至高一致.
- 患者报告的整体健康状况和残疾严重程度可能会影响药物自我报告的准确性.
相关概念视频
Genome-wide Association Studies-GWAS
15.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Combined Effects of Drugs: Antagonism
11.5K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.5K
Inflammatory Bowel Disease IV: Pharmacological Management
496
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
496
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484


